Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16201365 | 0.92 | HRH3 (0.42) | HRH3 | |
| SCHEMBL16201266 | 0.91 | CARM1 (0.41) | HRH3ALDH1A1CHEK1HTTLRRK2 | |
| SCHEMBL16204205 | 0.89 | PRMT1 (0.43) | HRH3ALDH1A1 | |
| SCHEMBL16201379 | 0.85 | ALDH1A1 (0.40) | HRH3ALDH1A1HTTL3MBTL1AXL | |
| SCHEMBL16201204 | 0.82 | CARM1 (0.45) | HRH3 | |
| SCHEMBL17758405 | 0.81 | PRMT1 (0.47) | HRH3 | |
| SCHEMBL16201414 | 0.79 | PRMT1 (0.41) | ALDH1A1L3MBTL1GAA | |
| SCHEMBL17758391 | 0.79 | PRMT1 (0.50) | HRH3 | |
| SCHEMBL16201376 | 0.78 | KDM4E (0.36) | ALDH1A1 | |
| SCHEMBL16201419 | 0.78 | MEN1 (0.41) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776972-B2 | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof | EPIZYME INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9346761-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20140323537-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323537-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | HRH3 1068/4885ALDH1A1 686/4885GPR119 820/4885 |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | HRH3 928/4885ALDH1A1 895/4885GPR119 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.